Cochrane Abstracts
Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta‐analysis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Addition of Long‐acting Beta2 Agonists or Long‐acting Muscarinic Antagonists Versus Doubling the Dose of Inhaled Corticosteroids (ICS) in Adolescents and Adults With Uncontrolled Asthma With Medium Dose ICS: a Systematic Review and Network Meta‐analysis." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/440540/all/Addition_of_long‐acting_beta2_agonists_or_long‐acting_muscarinic_antagonists_versus_doubling_the_dose_of_inhaled_corticosteroids__ICS__in_adolescents_and_adults_with_uncontrolled_asthma_with_medium_dose_ICS:_a_systematic_review_and_network_meta‐analysis.
Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta‐analysis. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440540/all/Addition_of_long‐acting_beta2_agonists_or_long‐acting_muscarinic_antagonists_versus_doubling_the_dose_of_inhaled_corticosteroids__ICS__in_adolescents_and_adults_with_uncontrolled_asthma_with_medium_dose_ICS:_a_systematic_review_and_network_meta‐analysis. Accessed January 15, 2025.
Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta‐analysis. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440540/all/Addition_of_long‐acting_beta2_agonists_or_long‐acting_muscarinic_antagonists_versus_doubling_the_dose_of_inhaled_corticosteroids__ICS__in_adolescents_and_adults_with_uncontrolled_asthma_with_medium_dose_ICS:_a_systematic_review_and_network_meta‐analysis
Addition of Long‐acting Beta2 Agonists or Long‐acting Muscarinic Antagonists Versus Doubling the Dose of Inhaled Corticosteroids (ICS) in Adolescents and Adults With Uncontrolled Asthma With Medium Dose ICS: a Systematic Review and Network Meta‐analysis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/440540/all/Addition_of_long‐acting_beta2_agonists_or_long‐acting_muscarinic_antagonists_versus_doubling_the_dose_of_inhaled_corticosteroids__ICS__in_adolescents_and_adults_with_uncontrolled_asthma_with_medium_dose_ICS:_a_systematic_review_and_network_meta‐analysis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta‐analysis
ID - 440540
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/440540/all/Addition_of_long‐acting_beta2_agonists_or_long‐acting_muscarinic_antagonists_versus_doubling_the_dose_of_inhaled_corticosteroids__ICS__in_adolescents_and_adults_with_uncontrolled_asthma_with_medium_dose_ICS:_a_systematic_review_and_network_meta‐analysis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
